However, we have recently shown that LNCaP PCa cells chronically exposed to IL-1 for several months evolve resistance to exogenous IL-1 and acquire pro-tumorigenic phenotypes [16] that, as a consequence, can no longer be mitigated by IL-1Ra; thus, emphasizing the need for alternative target molecules and therapies against chronic IL-1-induced tumorigenicity. The gene discussed is IL1B; the disease is posterior cortical atrophy.